<DOC>
	<DOCNO>NCT01341834</DOCNO>
	<brief_summary>The purpose study : 1 . To determine optimal recommend phase II dose two investigational study drug , LBH589 RAD001 , give combination solid tumor ( With enrichment EBV-Driven tumor ) . 2 . To determine pharmacokinetic profile RAD001 combination two schedule LBH589 . 3 . To assess preliminary anti-tumor activity RAD001 LBH589 . This study also explore hypothesis HDACi mTOR inhibitor abrogate effect key viral protein , switch virus latent proliferative phase lytic phase . Immunologic correlate also examine ascertain T-cell subpopulation expression HLA class molecule . DCE-MRI subsequently employ dose expansion examine antiangiogenic effect .</brief_summary>
	<brief_title>Safety Tolerability Study RAD001 LBH589 All Solid Tumors With Enrichment EBV Driven Tumors</brief_title>
	<detailed_description>Dose escalation phase 1B study evaluate safety tolerability RAD001 combination LBH589 solid tumor , lymphoma ; enrich EBV driven tumor . The phase 2 component single arm , non-randomized study restrict nasopharyngeal carinoma ( endemic type ) . A `` 3+3 '' dose escalation design adopt . Patients start take LBH589 three time week run period one week , follow continous administration RAD001 week 2 . Pharmacokinetic assessment do day 1 LBH589 administration day 1 concurrent administration LBH589 + RAD001 . ON day 31 , one week drug holiday . This do explore eliminaition kinetics steady state , well durability target modulation . AEs patient monitor closely . In event grade 3/4 toxicity , cohort expand 6 . Dose escalation LBH589/RAD001 may proceed maximum tolerate dose ( MTD ) reach . Once MTD establish , expasion cohort comprise 20 EBV driven tumor open two different LBH589 dose schedule . Treatment continue progression disease , unacceptable toxcity , discontinuation criterion meet .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Inclusion criterion 1 . Patients histologically cytologically confirm solid malignancy lymphoma metastatic unresectable , standard curative palliative measure exist longer effective . For enrichment dose expansion phase : Only patient EBVrelated tumor , include nasopharyngeal carcinoma , well tumor know EBVrelated include ( limited ) gastric carcinoma ( 1015 % ) , lymphoma . These tumor ( NPC exclude ) : ) EBER situ hybridisation paraffin samples/ circulate tumor cell ; ii ) Elevated pretreatment serum EBV viral titre 2 . Patients prior treatment mTOR inhibitor HDAC inhibitor allow ONLY dose escalation phase 3 . Age ≥ 21 year old . 4 . Performance status ≤ 2 ( ECOG scale ) . 5 . Target lesion spiral CT MRI scan must least one diameter &gt; 1 cm ( conventional CT scan indicator lesion must least one diameter &gt; 2 cm ) ( dose expansion ) . 6 . Adequate bone marrow reserve : absolute granulocyte count &gt; 1 x 109/L , hemoglobin &gt; 8 g/dL platelet count &gt; 100,000/dL . 7 . Adequate hepatic function ( serum total bilirubin level &lt; 1.5 x ULN ; alanine transaminase ( ALT ) aspartate transaminase ( AST ) less 3 time ULN . 8 . Adequate renal function ( creatinine &lt; 1.5 time ULN ) . 9 . Normal ECG baseline significant conduction abnormality QTc ≤ 450 . 10 . Left Ventricular Ejection Fraction ≥ 50 % assessed MUGA scan echocardiography screening . 11 . No concurrent use investigational antineoplastic therapy . 12 . No medical problem severe enough prevent compliance study requirement 13 . Negative pregnancy test ( urinary βHCG ) screening ( applicable woman child bear potential sexually active ) . 14 . Subjects must sign informed consent document indicate understand purpose procedure require study willing participate study . 1 . Known brain metastasis ( locally advance NPC direct extension central nervous system permissible ) . 2 . Chemotherapy ( case nitrosoureas mitomycin C within 6 week ) , radiotherapy , immunotherapy within 4 week study drug administration . 3 . Patients receive chronic immunosuppressive treatment high dose corticosteroid ( tail dos low dos acceptable ) another immunosuppressive agent ; 4 . Patients uncontrolled diabetes ( fast glucose &gt; 2x ULN ) ; 5 . History uncontrolled heart disease ( unstable angina , congestive heart failure , myocardial infarction within precede 12 month , clinically significant rhythm conduction abnormality second third degree heart block , congenital long QT syndrome , obligate use cardiac pacemaker . Patients QTc screen &gt; 450 ms. 6 . Subjects take medication know risk cause cause QTc prolongation Torsades de Pointes ( risk group 1 indicated webpage : http : //www.torsades.org ) . 7 . Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment . 8 . Patients impairment GI function GI disease may significantly alter panobinostat absorption . 9 . Patients unresolved diarrhea grade 2 . 10 . Patients known history Hepatitis B , C HIV seropositivity . 11 . Patients active bleeding diathesis ; 12 . Subjects Grade ≥ 2 neuropathy baseline . 13 . For patient undergoing magnetic resonance imaging ( MRI ) study ( include DCEMRI , BOLDMRI DWIMRI ) expansion cohort : 1 . Contraindications MRI , e.g . contraindicate metal implant 2 . Patients poor antecubital fossa venous access .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nasopharyngeal carcinoma , antiangiogenesis , HDACi , mTOR , Phase Ib</keyword>
</DOC>